Cardiff Oncology, Inc. (CRDF)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Cardiff Oncology, Inc. reported revenue of $593.0K, down 13.2% from the prior year. The company ran a net loss, with a net margin of -7732.0%. It held $61.88M in total assets against $16.50M in total liabilities.
Key ratios (FY2025)
-8256.3%
Operating margin
-7732.0%
Net margin
-101.0%
Return on equity
-13.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.0K | $683.0K | $488.0K | $386.0K | $359.0K | $366.0K | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | $0 | $597.5K | $1.81M | $1.73M |
| Operating Income | -$48.96M | -$48.65M | -$45.41M | -$39.90M | -$28.86M | -$19.09M | -$16.68M | -$17.05M | -$25.60M | -$40.15M |
| Net Income | -$45.85M | -$45.43M | -$41.44M | -$38.70M | -$28.29M | -$19.31M | -$16.41M | -$16.46M | -$24.91M | -$39.20M |
| EPS (Diluted) | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 | — | $-8.26 | $-51.76 | $-1.37 |
| Total Assets | $61.88M | $97.19M | $81.64M | $116.19M | $149.54M | $134.73M | $13.09M | $14.17M | $12.28M | $43.95M |
| Total Liabilities | $16.50M | $14.24M | $11.90M | $9.85M | $9.13M | $6.57M | $5.78M | $4.09M | $5.78M | $24.18M |
| Shareholders' Equity | $45.39M | $82.95M | $69.74M | $106.34M | $140.42M | $128.16M | $7.31M | $10.08M | $6.51M | $19.77M |
| Cash & Equivalents | $17.47M | $51.47M | $21.66M | $16.35M | $11.94M | $130.98M | $10.20M | $11.45M | $8.23M | $13.92M |
| Operating Cash Flow | -$37.92M | -$37.69M | -$30.89M | -$33.82M | -$23.04M | -$16.32M | -$13.27M | -$13.20M | — | — |
| Capital Expenditures | $44.0K | $80.0K | $582.0K | $1.01M | $205.0K | $211.0K | $67.6K | $5.1K | $101.1K | $823.5K |
| Shares Outstanding | 68.31M | 66.52M | 44.68M | 44.68M | 41.96M | 36.78M | 8.59M | 3.83M | 733.2K | 30.70M |